It will be important to evaluate the presence and features of ADAMTSL5-specific T-cell responses in oncological patients developing chronic psoriasis following anti-PD-1 therapies, and to assess whether these responses may concomitantly trigger the onset of psoriasis and the protection against tumor. Here, PDCD1 is linked to psoriasis.